Macular Edema following Retinal Vein Occlusion MEfRVO Macular Edema following Retinal Vein Occlusion MEfRVO

Macular Edema
following Retinal
Vein Occlusion (MEfRVO)


MEfRVO may try to slow your eyes down. EYLEA may be able to help.

WHAT IS RVO?

RVO (Retinal Vein Occlusion) occurs when a blood vessel in the retina becomes blocked, often by a blood clot. This blockage can cause fluid to leak into the macula, which can cause vision loss or blurring.

Learn about MEfRVO
Macular Edema following Retinal Vein Occlusion MEfRVO

See the results of EYLEA

EYLEA has been studied in more than 3,000 people with certain diseases of the retina. Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with MEfRVO.

EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Learn how EYLEA may be able to help
View study results for EYLEA, an anti-VEGF treatment for patients with MEfRVO. View study results for EYLEA, an anti-VEGF treatment for patients with MEfRVO.
Frequently asked questions about Macular Edema following Retinal Vein Occlusion

FREQUENTLY ASKED QUESTIONS

Have questions about EYLEA or MEfRVO? We have answers.

See the FAQs

FINANCIAL SUPPORT FROM EYLEA4U®

TIPS FOR LIVING WITH LOW VISION

SAFETY WITH EYLEA

EYLEA4U is a comprehensive support program with several resources available to help eligible patients with the cost of EYLEA.

Just a few changes may make a big difference in your daily routine.

Read about possible side effects, what you should tell your doctor before you receive EYLEA, and more.

IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2019, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

03/2019
US-LEA-14281d(1) US-LEA-14281d(1)

 

Searching with Lea

Close
MENU